Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115618 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Maxim Girod und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fluorouracil, Oncolytic Virotherapy, MicroRNAs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander Stiftung, Technische Universität Berlin, Wilhem Sander-Stiftung.
Abstract (Originalsprache)
FOLFOXIRI chemotherapy is a first-line therapy for advanced or metastatic colorectal cancer (CRC), yet its therapeutic efficacy remains limited. Immunostimulatory therapies like oncolytic viruses can complement chemotherapies by fostering the infiltration of the tumor by immune cells and enhancing drug cytotoxicity. In this study, we explored the effect of combining the FOLFOXIRI chemotherapeutic agents with the oncolytic coxsackievirus B3 (CVB3) PD-H in the CRC cell line Colo320. Additionally, we examined the impact of the drugs on the expression of microRNAs (miRs), which could be used to increase the safety of oncolytic CVB3 containing corresponding miR target sites (miR-TS). The measurement of cytotoxic activity using the Chou–Talalay combination index approach revealed that PD-H synergistically enhanced the cytotoxic activity of oxaliplatin (OX), 5-fluorouracil (5-FU) and SN-38. PD-H replication was not affected by OX and SN-38 but inhibited by high concentrations of 5-FU. MiR expression levels were not or only slightly elevated by the drugs or with drug/PD-H combinations on Colo320 cells. Moreover, the drug treatment did not increase the mutation rate of the miR-TS inserted into the PD-H genome. The results demonstrate that the combination of FOLFOXIRI drugs and PD-H may be a promising approach to enhance the therapeutic effect of FOLFOXIRI therapy in CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 10623 Berlin, Germany.
- Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
ORCID-Profile: Antje Beling, Jens Kurreck, Henry Fechner
Förderung
- Wilhelm Sander Stiftung
- Technische Universität Berlin
- Wilhem Sander-Stiftung
- TU Berlin internal funding ProTuTec
Zitieren
APA
Girod, M., Geisler, A., Hinze, L., Elsner, L., Dieringer, B., Beling, A., Kurreck, J., & Fechner, H. (2024). Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115618
Vancouver
Girod M, Geisler A, Hinze L, Elsner L, Dieringer B, Beling A, et al. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115618
BibTeX
@article{Girod2024,
author = {Girod, Maxim and Geisler, Anja and Hinze, Luisa and Elsner, Leslie and Dieringer, Babette and Beling, Antje and Kurreck, Jens and Fechner, Henry},
title = {Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115618}
}
EUVIMED